Related Experiment Video
Updated: Oct 2, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Carrier-Free CXCR4-Targeted Nanoplexes Designed for Polarizing Macrophages to Suppress Tumor Growth
Michael B Deci1, Maixian Liu1, Jacqueline Gonya1
1Department of Pharmaceutical Sciences, School of Pharmacy, University at Buffalo, The State University of New York, Buffalo, NY 14214 USA.
Introduction:
Treatment options for cancer metastases, the primary cause of cancer mortality, are limited. The chemokine receptor CXCR4 is an attractive therapeutic target in cancer because it mediates metastasis by inducing cancer cell and macrophage migration. Here we engineered carrier-free CXCR4-targeting RNA-protein nanoplexes that not only inhibited cellular migration but also polarized macrophages to the M1 phenotype.
Materials And Methods:
A CXCR4-targeting single-chain variable fragment (scFv) antibody was fused to a 3030 Da RNA-binding protamine peptide (RSQSRSRYYRQRQRSRRRRRRS). Self-assembling nanoplexes were formed by mixing the CXCR4-scFv-protamine fusion protein (CXCR4-scFv-RBM) with miR-127-5p, a miRNA shown to mediate M1 macrophage polarization. RNA-protein nanoplexes were characterized with regard to their physicochemical properties and therapeutic efficacy.
Results:
CXCR4-targeting RNA-protein nanoplexes simultaneously acted as a targeting ligand, a macrophage polarizing drug, and a miRNA delivery vehicle. Our carrier-free, RNA-protein nanoplexes specifically bound to CXCR4-positive macrophages and breast cancer cells, showed high drug loading (~ 90% w/w), and are non-toxic. Further, these RNA-protein nanoplexes significantly inhibited cancer and immune cell migration (75 to 99%), robustly polarized macrophages to the tumor-suppressive M1 phenotype, and inhibited tumor growth in a mouse model of triple-negative breast cancer.
Conclusions:
We engineered a novel class of non-toxic RNA-protein nanoplexes that modulate the tumor stroma. These nanoplexes are promising candidates for add-ons to clinically approved chemotherapeutics.
Insights
Researchers developed novel RNA-protein nanoplexes targeting CXCR4 to inhibit cancer metastasis and reprogram tumor-associated macrophages. These non-toxic nanoplexes show significant potential as combination therapy for aggressive cancers.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Biology
Background:
- Cancer metastasis remains a primary cause of cancer mortality with limited treatment options.
- The chemokine receptor CXCR4 is implicated in cancer cell and macrophage migration, driving metastasis.
- Targeting CXCR4 offers a promising strategy for developing novel anti-cancer therapies.
Purpose of the Study:
- To engineer novel, carrier-free RNA-protein nanoplexes targeting CXCR4.
- To evaluate the nanoplexes' ability to inhibit cancer cell migration and modulate the tumor microenvironment.
- To assess the therapeutic efficacy of these nanoplexes in preclinical cancer models.
Main Methods:
- Fusion of a CXCR4-targeting single-chain variable fragment (scFv) antibody with an RNA-binding protamine peptide.
- Self-assembly of nanoplexes using the fusion protein and miR-127-5p for M1 macrophage polarization.
- Characterization of nanoplex physicochemical properties and in vitro/in vivo therapeutic evaluation.
Main Results:
- Developed non-toxic, carrier-free RNA-protein nanoplexes with high drug loading (~90% w/w).
- Nanoplexes specifically bound CXCR4-positive cells and significantly inhibited cancer and immune cell migration (75-99%).
- Demonstrated robust M1 macrophage polarization and significant inhibition of tumor growth in a triple-negative breast cancer mouse model.
Conclusions:
- Engineered a novel class of non-toxic RNA-protein nanoplexes that effectively modulate the tumor stroma.
- These nanoplexes show promise as a new therapeutic strategy for cancer metastasis.
- The developed nanoplexes are potential candidates for combination therapy with existing chemotherapeutics.
More Related Videos
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
